37 results about "Leptin receptor" patented technology

Methods of regulating angiogenesis, ischemic injury and/or wound healing by modulating the activity of leptin, particularly as mediated by the leptin receptor, and/or the interaction between leptin and the leptin receptor. Correspondingly, these methods can also be used to treat diseases mediated by angiogenesis, including wound healing, tumors and tumor metastasis, diabetic microangiopathy, retinal neovascularization, neovascularization of adipose tissue and fat metabolism, revascularization of necrotic tissue, enhancement or vascularization in microvascular transplants, and ovarian follicle maturation. Assays for identifying agents that modulate leptin and/or leptin receptor-mediated angiogenesis and/or wound healing and their use in treating angiogenesis-mediated diseases or conditions involving wound healing are also disclosed.

The present application relates to new compounds of formula (I),

to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

A method of treating prostate cancer in a prostate cancer patient is disclosed. In one embodiment of the present invention, the method comprises the step of decreasing or blocking the patient's leptin interaction with leptin receptor or increasing adiponectin interaction with adiponectin receptors.

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.

The invention relates to the field of in vitro diagnostic reagents and in particular relates to a kit for detecting a soluble leptin receptor (sOB-R) by latex enhanced turbidimetric immunoassay. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is formed by a buffer solution 1, a stabilizing agent 1, a preservative 1, ethylene diamine tetraacetic acid (EDTA), a coagulant and a protective agent 1; the reagent R2 is formed by polystyrene latex microspheres crosslinked with an sOB-R antibody, buffer solutions 2, stabilizing agents 2, a preservative 2 and a protective agent 2; the polystyrene latex microspheres are connected with the sOB-R antibody by covalent crosslinking. The kit has the beneficial effects that latex enhanced turbidimetric immunoassay is adopted, and when the sOB-R in the blood reacts with the sOB-R antibody, polystyrene latexes are driven to gather to generate a certain turbidity, so that the kit is more convenient in detection and is easy to apply clinically.

Described are methods and compositions for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of Shp2 modulators to an animal, alone or in combination with body weight regulating agents are disclosed. Methods and compositions for treating a variety of disorders associated with or caused by undesirable body weight are also described. Also described are methods for identifying compounds useful for regulation of body weight and associated conditions. In particular, methods are disclosed for identification of compounds that preferentially modulate binding of Shp2 to leptin receptors. Also described is a genetically modified non-human animal model for studying the peripheral and central pathways of energy homeostasis. Also disclosed are methods of identifying compounds for regulating such pathways.

The present invention relates to a functional fragment of a receptor having a function in signaling. Particularly, the present invention relates to a functional fragment of the leptin receptor, involved in SOCS3, CIS and/or Vav signaling.

The invention relates to the field of in-vitro diagnostic reagents, and particularly relates to a soluble leptin receptor (sOB-R) latex reinforced immunonephelometry assay kit by utilizing a surface functional group. The assay kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is prepared from a buffer solution 1, a stabilizing agent 1, a preservative 1, EDTA, a gelling agent and a protective agent 1; the reagent R2 is prepared from polystyrene latex microspheres crosslinked with an sOB-R antibody, a buffer solution 2, a stabilizing agent 2, a preservative 2 and a protective agent 2; the polystyrene latex microspheres and the sOB-R antibody are connected by means of covalent cross-linking; the surface functional group of the polystyrene latex microspheres in the reagent R2 is amino, carboxyl, hydrazide, aldehyde or epoxy group. According to the assay kit, a latex reinforced immunonephelometry method is adopted, when the sOB-R in blood reacts with the sOB-R antibody, polystyrene latex is driven to aggregate and generate certain turbidity, so that the detection can be convenient. The sOB-R latex reinforced immunonephelometry assay kit is easily applied in clinical application.

The invention relates to the field of in vitro diagnostic reagents and in particular relates to an ion stabilizing agent and suspension stabilizing agent cooperatively used kit for detecting a soluble leptin receptor (sOB-R) by latex enhanced turbidimetric immunoassay. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is formed by a buffer solution 1, a stabilizing agent 1, a preservative 1, ethylene diamine tetraacetic acid (EDTA), a coagulant and a protective agent 1; the reagent R2 is formed by polystyrene latex microspheres crosslinked with an sOB-R antibody, buffer solutions 2, stabilizing agents 2, a preservative 2 and a protective agent 2; the polystyrene latex microspheres are connected with the sOB-R antibody by covalent crosslinking; the stabilizing agents 2 in the reagent R2 are an ion stabilizing agent and a suspension stabilizing agent, which are cooperatively used. The kit has the beneficial effects that latex enhanced turbidimetric immunoassay is adopted, and when the sOB-R in the blood reacts with the sOB-R antibody, polystyrene latexes are driven to gather to generate a certain turbidity, so that the kit is more convenient in detection and is easy to apply clinically.

The invention discloses an Leptin receptor affinity peptide and an application thereof. The sequence of the Leptin receptor affinity peptide is as shown in SEQ ID No.1. The invention further discloses an affinity peptide with collagen binding capacity. The affinity peptide comprises the Leptin receptor affinity peptide and a short peptide with specific collagen binding capacity, and the short peptide with the specific collagen binding capacity is bound to the N end of the Leptin receptor affinity peptide. The affinity peptide has high affinity with a Leptin receptor and can be specifically bound with MSC, the affinity peptide is connected to a biological material, and the affinity peptide connected with the short peptide with the specific collagen binding capacity can achieve specific binding with a collagen scaffold, so that the recruitment of the biological material on the MSC with the surface expressing the Leptin receptor is improved, a better tissue damage repair effect is obtained, and an experimental basis is provided for researching the MSC in the aspects of tissue engineering repair and targeted therapy research.

The present invention relates to identification of a receptor for a satiety factor, which is involved in body weight homeostasis. Mutations in this receptor are associated with obese phenotypes. In particular, the present invention relates to identification and characterization of the receptor for leptin, including a naturally occurring soluble form of the receptor that is expected to modulate leptin activity, in particular to agonize leptin activity. The invention further relates to the nucleic acids encoding the receptor, and to methods for using the receptor, e.g., to identify leptin analogs, therapeutically, such as in gene therapy or in soluble form as an agonist or antagonist of leptin activity, or diagnostically.

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

The invention provides a rutundic acid R as a leptin sensitizer as well as application thereof in preparation of weight-reducing medicines. The in-vitro mechanism studies show that the rotundic acid Rcan significantly reduce the food intake of a mouse fed with high fat diet (HFD) so as to reduce the weight of the mouse; and the weight reduction effect on normal lean mice and mice lacking leptin receptors are weak. Besides, the body fat of the HFD-fed mouse can be reduced obviously by the rotundic acid R; and the fat browning and expression of fatty acid oxidation genes can be promoted by activating the mitochondrial function and the browning of subcutaneous white fat of the mouse is accelerated. The phosphorylation of downstream STAT3 is promoted by possibly inhibiting the activity of PTP1B, so that the sensitivity of a leptin receptor is improved and thus the effect of reducing weight is realized.